α-葡萄糖苷酶
α-葡萄糖苷酶结构式
|
常用名 | α-葡萄糖苷酶 | 英文名 | α-Glucosidase |
|---|---|---|---|---|
| CAS号 | 9001-42-7 | 分子量 | N/A | |
| 密度 | N/A | 沸点 | N/A | |
| 分子式 | N/A | 熔点 | N/A | |
| MSDS | 美版 | 闪点 | N/A |
|
In vitro and in vivo effects of standardized extract and fractions of Phaleria macrocarpa fruits pericarp on lead carbohydrate digesting enzymes.
BMC Complement Altern. Med. 13 , 39, (2013) One vital therapeutic approach for the treatment of type 2 diabetes mellitus is the use of agents that can decrease postprandial hyperglycaemia by inhibiting carbohydrate digesting enzymes. The present study investigated the effects of bioassay-guided extract... |
|
|
Enzymatic properties of a thermostable α-glucosidase from acidothermophilic crenarchaeon Sulfolobus tokodaii strain 7.
J. Microbiol. Biotechnol. 23(1) , 56-63, (2013) We have characterized the putative α-glucosidase gene (st2525) selected by total genome analysis from the acidothermophilic crenarchaeon Sulfolobus tokodaii strain 7. The ORF was cloned and expressed as a fusion protein in Escherichia coli, and recombinant ST... |
|
|
Identification of the first deletion-insertion involving the complete structure of GAA gene and part of CCDC40 gene mediated by an Alu element.
Gene 519(1) , 169-72, (2013) Pompe disease is an uncommon autosomal recessive glycogen storage disorder caused by deficiency of acid α-glucosidase. Classic infantile form triggers severe cardiomyopathy, hypotonia, and respiratory failure, leading to death within the first two years of li... |
|
|
Detection of a novel mutation in the GAA gene in an Iranian child with glycogen storage disease type II.
Arch. Iran. Med. 16(2) , 126-8, (2013) Glycogen storage disease II (GSDII or Pompe disease, OMIM # 232300) is an autosomal recessive hereditary lysosomal disorder. Mutations in the GAA gene usually lead to reduced acid α-glucosidase (acid maltase, GAA, OMIM *606800, EC 3.1.26.2) activity, which re... |
|
|
In vitro anti-diabetic activity of Sclerocarya birrea and Ziziphus mucronata.
Nat. Prod. Commun. 8(9) , 1279-84, (2013) Type 2 diabetes mellitus is on the increase worldwide. Current treatments possess undesirable side-effects and therefore investigations into alternative remedies, which may be cost-effective and devoid of such side-effects, are on-going. Aqueous and methanol ... |
|
|
Purification of rabbit intestinal glucoamylase by affinity chromatography on Sephadex G-200.
Indian J. Biochem. Biophys. 10(4) , 283-4, (1973)
|
|
|
Pharmacokinetic comparisons between two formulations containing 100 mg of miglitol in healthy male Korean volunteers: a randomized, open-label, single-dose, two-period, two-sequence crossover bioequivalence study.
Int. J. Clin. Pharmacol. Ther. 52(1) , 55-63, (2014) Miglitol is an α-glucosidase inhibitor (AGI) used as an antihyperglycemic agent in the treatment of type 2 diabetes mellitus. The mechanism is that miglitol binds to and inhibits the α-glucosidase reversibly in the proximal intestine. Thus, carbohydrates not ... |
|
|
Further kinetic and structural characterization of the lysosomal alpha-D-glucoside glucohydrolase from cattle liver.
Biochim. Biophys. Acta 212(3) , 470-7, (1970)
|
|
|
Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy.
Neurology 80(12) , 1173, (2013)
|
|
|
Low-frequency enzyme replacement therapy in late-onset Pompe disease.
Muscle Nerve 47(4) , 612-3, (2013)
|